Significant Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 16, 2021	Feb. 09, 2021	May 15, 2020	Jul. 13, 2015	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 15, 2016	Jul. 16, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
General and administrative					$ 10,044	$ 5,113
Increase decrease in fair value of success payments liability						500
Deferred revenue, net of current portion					0		$ 0		$ 100
Deferred revenue, net of current portion ($0 and $100 from related party, respectively)					15,626		15,626		22,032
Contract Based Intangible Assets
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues							1,100	$ 200
Accounts Receivable
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues							400		1,000
Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payment										$ 2,800
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future development, regulatory, and product launch milestones payment received			$ 200,000
Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing expenses								800
The Regents of the University of California/University of Vienna
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Clinical milestone payment							3,400
Reimbursement percentage											50.00%
Reduction in general and administrative expenses					500	1,600	1,600
Patent prosecution and maintenance costs								3,200
The Regents of the University of California/University of Vienna | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing expenses					200	700	500	1,000
The Regents of the University of California/University of Vienna | General and Administrative Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Patent prosecution and maintenance costs					1,000	3,300	3,300	6,500
Memorial Sloan Kettering Cancer Center
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate success payment					35,000		35,000
Maximum value of success payments and control payment					35,000		35,000
Fair value of success payments liability					1,400		1,400
Increase decrease in fair value of success payments liability					$ 1,100		$ 2,600	1,200
Memorial Sloan Kettering Cancer Center | Series B Convertible Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share price					$ 5.1914		$ 5.1914
Intellia Therapeutics, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of other party's expenses												30.00%
Upfront cash payment	$ 1,000
Potential future milestone payments	$ 23,000
Intellia Therapeutics, Inc. | General and Administrative Expense | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Expenses incurred from transactions with related parties					$ 200			100
Intellia Therapeutics, Inc. | General and Administrative Expense | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Increase decrease in fair value of success payments liability						100
Expenses incurred from transactions with related parties							$ 400
Intellia Therapeutics, Inc. | General and Administrative Expense | Patents
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Increase decrease in fair value of success payments liability					200
Expenses incurred from transactions with related parties							500	1,300
Patent prosecution and maintenance costs						800
Pioneer Hi-Bred International, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront cash payment										500
Future contingent milestone payments				$ 22,400
Milestone Revenue				$ 300
Pioneer Hi-Bred International, Inc. | Sales Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payment										$ 20,000
Pioneer Hi-Bred International, Inc. | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing expenses					0	0	0
Private Company License Agreement | Convertible Preferred Stock [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Convertible preferred stock issued			7,500,000
Fair value of convertible preferred stock			$ 7,500
Collaboration and License Agreement with AbbVie
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues					2,900	$ 500	3,800	$ 500
Future development, regulatory, and product launch milestones payment received		$ 15,000	$ 150,000
Upfront cash payment received					30,000		30,000		30,000
Deferred revenue, net of current portion					12,100		12,100		8,300
Deferred revenue, net of current portion ($0 and $100 from related party, respectively)					$ 13,100		$ 13,100		$ 19,100